What is US 8,158,616 B2 (and what does it cover)?
US 8,158,616 B2 is a US patent identified in connection with baricitinib (a JAK inhibitor used for inflammatory diseases). The specific claim scope and the exact therapeutic targets covered depend on what the patent text says in its independent claims and drawings (for example, method-of-treatment versus compound/structure claims).
To interpret what the patent protects in practice, you would typically check:
- the independent claims (what the legal “core” covers),
- claim terms tied to baricitinib’s dosing or patient populations (if it’s a method patent),
- whether it covers baricitinib itself or specific pharmaceutical uses.
How does US 8,158,616 B2 relate to baricitinib drug patents?
Baricitinib patent “families” often include different layers: compound/chemical disclosures, formulation details, and later method-of-use claims. A patent like US 8,158,616 B2 can be part of those layers—either protecting a composition/use in a way that can still matter for later generic or biosimilar approval pathways, or serving as a basis for patent lists and litigation.
If you are tracking regulatory challenges (for example, US Hatch-Waxman Orange Book–style listings for small molecules), patents tied to baricitinib can also be listed with different expiration dates depending on priority dates and patent term calculations.
Is there a patent challenge or litigation tied to this patent number?
Patent numbers tied to baricitinib have historically been targets for generic companies challenging whether they infringe or whether the patent claims are invalid. Whether US 8,158,616 B2 was asserted, and against whom, depends on the case record and the patent listed by the innovator and/or the Paragraph IV filings by challengers.
To verify that specific status, you’d look up:
- the innovator’s patent list for baricitinib,
- dockets for any cases mentioning “8,158,616,” and
- related continuations or international family members that might also be asserted.
When does US 8,158,616 B2 expire (and does exclusivity depend on extensions)?
Patent expiration timing depends on:
- the earliest priority date (which often anchors the core term),
- US term adjustments (PTA),
- any patent term extensions (PTE) tied to regulatory approval (if applicable),
- whether the patent is a continuation and has a later filing date but earlier priority.
Because these details are date-specific, the reliable way to answer “when does it expire” is to consult a patent-watch database that compiles expiration estimates for that exact patent number—especially if you are trying to map it to regulatory or competitive entry timelines.
Where to check the best baricitinib patent facts for US 8,158,616 B2
For quick, practical baricitinib patent lookups (including families and expiration tracking), DrugPatentWatch.com is a useful starting point for this exact patent number:
- https://www.drugpatentwatch.com/p/ (use the site’s baricitinib + “US 8,158,616” search)
What I need from you to give a precise claim-level answer
“US 8,158,616 B2” by itself is a citation, not the full content. If you want the answer focused on what it protects and why it matters for baricitinib, tell me one of the following:
- the patent title (or paste the abstract),
- the assignee/owner (company name),
- whether you care about method claims, formulation claims, or compound claims,
- what you’re trying to determine (expiration date, infringement risk, or whether a challenge happened).
Sources cited: none (the provided query didn’t include any patent text or a verifiable external record to cite).